Cardiotoxicity of chemotherapeutic agents /:
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York :
Nova Science Publishers,
2017.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Beschreibung: | 1 online resource |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9781536121353 1536121355 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn991595824 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 170626s2017 nyu ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d N$T |d EBLCP |d OCLCF |d YDX |d AGLDB |d IGB |d AUW |d BTN |d MHW |d INTCL |d SNK |d A6Q |d G3B |d S8I |d S8J |d S9I |d STF |d D6H |d M8D |d OCLCQ |d K6U |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d OCLCL |d OCLCQ | ||
| 066 | |c (S | ||
| 020 | |a 9781536121353 |q (electronic bk.) | ||
| 020 | |a 1536121355 |q (electronic bk.) | ||
| 020 | |z 9781536121193 | ||
| 035 | |a (OCoLC)991595824 | ||
| 050 | 4 | |a RC667 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 7 | |a 616.12 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Cardiotoxicity of chemotherapeutic agents / |c Gregg M. Lanier, Jalaj Garg and Neeraj Shah, editors. |
| 264 | 1 | |a New York : |b Nova Science Publishers, |c 2017. | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | 0 | |a Online resource; title from PDF title page (EBSCO, viewed June 27, 2017) | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Preface; Chapter 1; Introduction: Cardiotoxicity of Chemotherapeutic Agents; Introduction; References; Chapter 2; Alkylating Agents; Cyclophosphamide; Ifosphamide (IFS); Carboplatin; Busulfan; Altretamine (Hexalen); Procarbazine; References; Chapter 3; Antimetabolites; 5-Fluorouracil; Raltitrexed (Tomudex); Cytosine Arabinoside (Cytarabine or Ara-C); Gemcitabine; Pentostatin; Other Antimetabolites; References; Chapter 4; Antitumor Antibiotics: Bleomycin and Mitoxantrone; Bleomycin; Mitoxantrone; References; Chapter 5 | |
| 505 | 8 | |a I. Electrocardiogram (EGC) Changes and Arrhythmias Associated with Anthracycline Useii. Chronic Cardiomyopathy; iii. Sub-Clinical Cardiotoxicity; Risk Factors Associated with Poor Long-Term Cardiovascular Outcomes; References; Chapter 7; Antitumor Antibiotics: Anthracyclines and Minimizing Cardiotoxicity; Approaches to Minimize Anthracycline Cardiotoxicity; 1. Pharmacokinetic Approaches for Cardiac Prevention; 2. Pharmacogenetic Approaches for Cardiac Prevention; 3. Chemo Protectants and Adjunctive Therapies to Reduce Cardiotoxicity; References; Chapter 8 | |
| 505 | 8 | |a Antitumor Antibiotics: Newer AnthracyclinesNew Anthracyclines; References; Chapter 9; Microtubule Inhibitors; Microtubule Inhibitors; Paclitaxel; Docetaxel; Vinca Alkaloids; Eribulin; Ixabepilone; References; Chapter 10; Hormonal Therapy; Estrogens; Aromatase Inhibitors; Progestins; Tamoxifen; Androgen Deprivation Therapy; Flutamide; Leuprolide; Cyproterone Acetate; References; Chapter 11; Immunotherapy; Interleukin; Interferon; References; Chapter 12; Monoclonal Antibodies; Trastuzumab; Rituximab; Alemtuzumab; Bevacizumab; Cetuximab; Gemtuzumab; Ibritumomab; Tositumomab; References | |
| 505 | 8 | |a Chapter 13Tyrosine Kinase Inhibitors; Imatinib; Dasatinib; Nilotinib; Sunitinib; Sorafenib; Lapatinib; Erlotinib and Geftinib; Other Tyrosine Kinase Inhibitors; References; Chapter 14; Topoisomerase-1 Inhibitors and Miscellaneous Drugs; Topoisomerase-1 Inhibitors; Irinotecan (CAMPTOSAR) and Topotecan (Hycamtin); Other Miscellaneous Drugs; Tretinoin; Arsenic Trioxide (Trisenox); References; About the Editors; Index; Blank Page | |
| 650 | 0 | |a Cardiology. |0 http://id.loc.gov/authorities/subjects/sh85020214 | |
| 650 | 0 | |a Chemotherapy. |0 http://id.loc.gov/authorities/subjects/sh85023041 | |
| 650 | 2 | |a Cardiology |0 https://id.nlm.nih.gov/mesh/D002309 | |
| 650 | 2 | |a Drug Therapy |0 https://id.nlm.nih.gov/mesh/D004358 | |
| 650 | 6 | |a Cardiologie. | |
| 650 | 6 | |a Chimiothérapie. | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Cardiology |2 fast | |
| 650 | 7 | |a Chemotherapy |2 fast | |
| 700 | 1 | |a Lanier, Gregg M., |e editor. | |
| 700 | 1 | |a Garg, Jalaj, |e editor. | |
| 700 | 1 | |a Shah, Neeraj, |e editor. | |
| 758 | |i has work: |a Cardiotoxicity of chemotherapeutic agents (Text) |1 https://id.oclc.org/worldcat/entity/E39PCFDpBTXfRBJhjv4Y7q79Mq |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1540068 |3 Volltext |
| 880 | 8 | |6 505-00/(S |a Antitumor Antibiotics: Anthracyclines, a Mechanism of CardiotoxicityAnthracyclines (Daunorubicin and Doxorubicin); Mechanisms of Anthracycline Toxicity; i. Reactive Oxygen Species and Redox Cycling; ii. Calcium Exchange Channels; iii. Role of GATA4; iv. Changes in Endogenous Adaptive Reserve of the Heart; v. Role of Topoisomerase 2β; vi. Role of Neuregulin-1, ErbB2, and ErbB4 Signalling; References; Chapter 6; Antitumor Antibiotics: Anthracyclines, Cardiotoxicity and Associated Risk Factors; Cardiotoxicity Caused by Anthracyclines | |
| 938 | |a YBP Library Services |b YANK |n 14440442 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL4882780 | ||
| 938 | |a EBSCOhost |b EBSC |n 1540068 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn991595824 |
|---|---|
| _version_ | 1816882393183682560 |
| adam_text | |
| any_adam_object | |
| author2 | Lanier, Gregg M. Garg, Jalaj Shah, Neeraj |
| author2_role | edt edt edt |
| author2_variant | g m l gm gml j g jg n s ns |
| author_facet | Lanier, Gregg M. Garg, Jalaj Shah, Neeraj |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC667 |
| callnumber-raw | RC667 |
| callnumber-search | RC667 |
| callnumber-sort | RC 3667 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | Preface; Chapter 1; Introduction: Cardiotoxicity of Chemotherapeutic Agents; Introduction; References; Chapter 2; Alkylating Agents; Cyclophosphamide; Ifosphamide (IFS); Carboplatin; Busulfan; Altretamine (Hexalen); Procarbazine; References; Chapter 3; Antimetabolites; 5-Fluorouracil; Raltitrexed (Tomudex); Cytosine Arabinoside (Cytarabine or Ara-C); Gemcitabine; Pentostatin; Other Antimetabolites; References; Chapter 4; Antitumor Antibiotics: Bleomycin and Mitoxantrone; Bleomycin; Mitoxantrone; References; Chapter 5 I. Electrocardiogram (EGC) Changes and Arrhythmias Associated with Anthracycline Useii. Chronic Cardiomyopathy; iii. Sub-Clinical Cardiotoxicity; Risk Factors Associated with Poor Long-Term Cardiovascular Outcomes; References; Chapter 7; Antitumor Antibiotics: Anthracyclines and Minimizing Cardiotoxicity; Approaches to Minimize Anthracycline Cardiotoxicity; 1. Pharmacokinetic Approaches for Cardiac Prevention; 2. Pharmacogenetic Approaches for Cardiac Prevention; 3. Chemo Protectants and Adjunctive Therapies to Reduce Cardiotoxicity; References; Chapter 8 Antitumor Antibiotics: Newer AnthracyclinesNew Anthracyclines; References; Chapter 9; Microtubule Inhibitors; Microtubule Inhibitors; Paclitaxel; Docetaxel; Vinca Alkaloids; Eribulin; Ixabepilone; References; Chapter 10; Hormonal Therapy; Estrogens; Aromatase Inhibitors; Progestins; Tamoxifen; Androgen Deprivation Therapy; Flutamide; Leuprolide; Cyproterone Acetate; References; Chapter 11; Immunotherapy; Interleukin; Interferon; References; Chapter 12; Monoclonal Antibodies; Trastuzumab; Rituximab; Alemtuzumab; Bevacizumab; Cetuximab; Gemtuzumab; Ibritumomab; Tositumomab; References Chapter 13Tyrosine Kinase Inhibitors; Imatinib; Dasatinib; Nilotinib; Sunitinib; Sorafenib; Lapatinib; Erlotinib and Geftinib; Other Tyrosine Kinase Inhibitors; References; Chapter 14; Topoisomerase-1 Inhibitors and Miscellaneous Drugs; Topoisomerase-1 Inhibitors; Irinotecan (CAMPTOSAR) and Topotecan (Hycamtin); Other Miscellaneous Drugs; Tretinoin; Arsenic Trioxide (Trisenox); References; About the Editors; Index; Blank Page |
| ctrlnum | (OCoLC)991595824 |
| dewey-full | 616.12 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.12 |
| dewey-search | 616.12 |
| dewey-sort | 3616.12 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05329cam a2200685 i 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn991595824</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">170626s2017 nyu ob 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">N$T</subfield><subfield code="d">EBLCP</subfield><subfield code="d">OCLCF</subfield><subfield code="d">YDX</subfield><subfield code="d">AGLDB</subfield><subfield code="d">IGB</subfield><subfield code="d">AUW</subfield><subfield code="d">BTN</subfield><subfield code="d">MHW</subfield><subfield code="d">INTCL</subfield><subfield code="d">SNK</subfield><subfield code="d">A6Q</subfield><subfield code="d">G3B</subfield><subfield code="d">S8I</subfield><subfield code="d">S8J</subfield><subfield code="d">S9I</subfield><subfield code="d">STF</subfield><subfield code="d">D6H</subfield><subfield code="d">M8D</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">K6U</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="066" ind1=" " ind2=" "><subfield code="c">(S</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781536121353</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1536121355</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781536121193</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)991595824</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC667</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">HEA</subfield><subfield code="x">039000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">014000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">022000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">112000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">045000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.12</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Cardiotoxicity of chemotherapeutic agents /</subfield><subfield code="c">Gregg M. Lanier, Jalaj Garg and Neeraj Shah, editors.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York :</subfield><subfield code="b">Nova Science Publishers,</subfield><subfield code="c">2017.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Online resource; title from PDF title page (EBSCO, viewed June 27, 2017)</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Preface; Chapter 1; Introduction: Cardiotoxicity of Chemotherapeutic Agents; Introduction; References; Chapter 2; Alkylating Agents; Cyclophosphamide; Ifosphamide (IFS); Carboplatin; Busulfan; Altretamine (Hexalen); Procarbazine; References; Chapter 3; Antimetabolites; 5-Fluorouracil; Raltitrexed (Tomudex); Cytosine Arabinoside (Cytarabine or Ara-C); Gemcitabine; Pentostatin; Other Antimetabolites; References; Chapter 4; Antitumor Antibiotics: Bleomycin and Mitoxantrone; Bleomycin; Mitoxantrone; References; Chapter 5</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">I. Electrocardiogram (EGC) Changes and Arrhythmias Associated with Anthracycline Useii. Chronic Cardiomyopathy; iii. Sub-Clinical Cardiotoxicity; Risk Factors Associated with Poor Long-Term Cardiovascular Outcomes; References; Chapter 7; Antitumor Antibiotics: Anthracyclines and Minimizing Cardiotoxicity; Approaches to Minimize Anthracycline Cardiotoxicity; 1. Pharmacokinetic Approaches for Cardiac Prevention; 2. Pharmacogenetic Approaches for Cardiac Prevention; 3. Chemo Protectants and Adjunctive Therapies to Reduce Cardiotoxicity; References; Chapter 8</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Antitumor Antibiotics: Newer AnthracyclinesNew Anthracyclines; References; Chapter 9; Microtubule Inhibitors; Microtubule Inhibitors; Paclitaxel; Docetaxel; Vinca Alkaloids; Eribulin; Ixabepilone; References; Chapter 10; Hormonal Therapy; Estrogens; Aromatase Inhibitors; Progestins; Tamoxifen; Androgen Deprivation Therapy; Flutamide; Leuprolide; Cyproterone Acetate; References; Chapter 11; Immunotherapy; Interleukin; Interferon; References; Chapter 12; Monoclonal Antibodies; Trastuzumab; Rituximab; Alemtuzumab; Bevacizumab; Cetuximab; Gemtuzumab; Ibritumomab; Tositumomab; References</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Chapter 13Tyrosine Kinase Inhibitors; Imatinib; Dasatinib; Nilotinib; Sunitinib; Sorafenib; Lapatinib; Erlotinib and Geftinib; Other Tyrosine Kinase Inhibitors; References; Chapter 14; Topoisomerase-1 Inhibitors and Miscellaneous Drugs; Topoisomerase-1 Inhibitors; Irinotecan (CAMPTOSAR) and Topotecan (Hycamtin); Other Miscellaneous Drugs; Tretinoin; Arsenic Trioxide (Trisenox); References; About the Editors; Index; Blank Page</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cardiology.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85020214</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Chemotherapy.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85023041</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Cardiology</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D002309</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Drug Therapy</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D004358</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Cardiologie.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Chimiothérapie.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS</subfield><subfield code="x">Diseases</subfield><subfield code="x">General.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Clinical Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Diseases.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Evidence-Based Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Internal Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cardiology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemotherapy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lanier, Gregg M.,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Garg, Jalaj,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shah, Neeraj,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Cardiotoxicity of chemotherapeutic agents (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCFDpBTXfRBJhjv4Y7q79Mq</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1540068</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="880" ind1="8" ind2=" "><subfield code="6">505-00/(S</subfield><subfield code="a">Antitumor Antibiotics: Anthracyclines, a Mechanism of CardiotoxicityAnthracyclines (Daunorubicin and Doxorubicin); Mechanisms of Anthracycline Toxicity; i. Reactive Oxygen Species and Redox Cycling; ii. Calcium Exchange Channels; iii. Role of GATA4; iv. Changes in Endogenous Adaptive Reserve of the Heart; v. Role of Topoisomerase 2β; vi. Role of Neuregulin-1, ErbB2, and ErbB4 Signalling; References; Chapter 6; Antitumor Antibiotics: Anthracyclines, Cardiotoxicity and Associated Risk Factors; Cardiotoxicity Caused by Anthracyclines</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">14440442</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL4882780</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">1540068</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-ocn991595824 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:27:54Z |
| institution | BVB |
| isbn | 9781536121353 1536121355 |
| language | English |
| oclc_num | 991595824 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource |
| psigel | ZDB-4-EBA |
| publishDate | 2017 |
| publishDateSearch | 2017 |
| publishDateSort | 2017 |
| publisher | Nova Science Publishers, |
| record_format | marc |
| spelling | Cardiotoxicity of chemotherapeutic agents / Gregg M. Lanier, Jalaj Garg and Neeraj Shah, editors. New York : Nova Science Publishers, 2017. 1 online resource text txt rdacontent computer c rdamedia online resource cr rdacarrier Online resource; title from PDF title page (EBSCO, viewed June 27, 2017) Includes bibliographical references and index. Preface; Chapter 1; Introduction: Cardiotoxicity of Chemotherapeutic Agents; Introduction; References; Chapter 2; Alkylating Agents; Cyclophosphamide; Ifosphamide (IFS); Carboplatin; Busulfan; Altretamine (Hexalen); Procarbazine; References; Chapter 3; Antimetabolites; 5-Fluorouracil; Raltitrexed (Tomudex); Cytosine Arabinoside (Cytarabine or Ara-C); Gemcitabine; Pentostatin; Other Antimetabolites; References; Chapter 4; Antitumor Antibiotics: Bleomycin and Mitoxantrone; Bleomycin; Mitoxantrone; References; Chapter 5 I. Electrocardiogram (EGC) Changes and Arrhythmias Associated with Anthracycline Useii. Chronic Cardiomyopathy; iii. Sub-Clinical Cardiotoxicity; Risk Factors Associated with Poor Long-Term Cardiovascular Outcomes; References; Chapter 7; Antitumor Antibiotics: Anthracyclines and Minimizing Cardiotoxicity; Approaches to Minimize Anthracycline Cardiotoxicity; 1. Pharmacokinetic Approaches for Cardiac Prevention; 2. Pharmacogenetic Approaches for Cardiac Prevention; 3. Chemo Protectants and Adjunctive Therapies to Reduce Cardiotoxicity; References; Chapter 8 Antitumor Antibiotics: Newer AnthracyclinesNew Anthracyclines; References; Chapter 9; Microtubule Inhibitors; Microtubule Inhibitors; Paclitaxel; Docetaxel; Vinca Alkaloids; Eribulin; Ixabepilone; References; Chapter 10; Hormonal Therapy; Estrogens; Aromatase Inhibitors; Progestins; Tamoxifen; Androgen Deprivation Therapy; Flutamide; Leuprolide; Cyproterone Acetate; References; Chapter 11; Immunotherapy; Interleukin; Interferon; References; Chapter 12; Monoclonal Antibodies; Trastuzumab; Rituximab; Alemtuzumab; Bevacizumab; Cetuximab; Gemtuzumab; Ibritumomab; Tositumomab; References Chapter 13Tyrosine Kinase Inhibitors; Imatinib; Dasatinib; Nilotinib; Sunitinib; Sorafenib; Lapatinib; Erlotinib and Geftinib; Other Tyrosine Kinase Inhibitors; References; Chapter 14; Topoisomerase-1 Inhibitors and Miscellaneous Drugs; Topoisomerase-1 Inhibitors; Irinotecan (CAMPTOSAR) and Topotecan (Hycamtin); Other Miscellaneous Drugs; Tretinoin; Arsenic Trioxide (Trisenox); References; About the Editors; Index; Blank Page Cardiology. http://id.loc.gov/authorities/subjects/sh85020214 Chemotherapy. http://id.loc.gov/authorities/subjects/sh85023041 Cardiology https://id.nlm.nih.gov/mesh/D002309 Drug Therapy https://id.nlm.nih.gov/mesh/D004358 Cardiologie. Chimiothérapie. HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Cardiology fast Chemotherapy fast Lanier, Gregg M., editor. Garg, Jalaj, editor. Shah, Neeraj, editor. has work: Cardiotoxicity of chemotherapeutic agents (Text) https://id.oclc.org/worldcat/entity/E39PCFDpBTXfRBJhjv4Y7q79Mq https://id.oclc.org/worldcat/ontology/hasWork FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1540068 Volltext 505-00/(S Antitumor Antibiotics: Anthracyclines, a Mechanism of CardiotoxicityAnthracyclines (Daunorubicin and Doxorubicin); Mechanisms of Anthracycline Toxicity; i. Reactive Oxygen Species and Redox Cycling; ii. Calcium Exchange Channels; iii. Role of GATA4; iv. Changes in Endogenous Adaptive Reserve of the Heart; v. Role of Topoisomerase 2β; vi. Role of Neuregulin-1, ErbB2, and ErbB4 Signalling; References; Chapter 6; Antitumor Antibiotics: Anthracyclines, Cardiotoxicity and Associated Risk Factors; Cardiotoxicity Caused by Anthracyclines |
| spellingShingle | Cardiotoxicity of chemotherapeutic agents / Preface; Chapter 1; Introduction: Cardiotoxicity of Chemotherapeutic Agents; Introduction; References; Chapter 2; Alkylating Agents; Cyclophosphamide; Ifosphamide (IFS); Carboplatin; Busulfan; Altretamine (Hexalen); Procarbazine; References; Chapter 3; Antimetabolites; 5-Fluorouracil; Raltitrexed (Tomudex); Cytosine Arabinoside (Cytarabine or Ara-C); Gemcitabine; Pentostatin; Other Antimetabolites; References; Chapter 4; Antitumor Antibiotics: Bleomycin and Mitoxantrone; Bleomycin; Mitoxantrone; References; Chapter 5 I. Electrocardiogram (EGC) Changes and Arrhythmias Associated with Anthracycline Useii. Chronic Cardiomyopathy; iii. Sub-Clinical Cardiotoxicity; Risk Factors Associated with Poor Long-Term Cardiovascular Outcomes; References; Chapter 7; Antitumor Antibiotics: Anthracyclines and Minimizing Cardiotoxicity; Approaches to Minimize Anthracycline Cardiotoxicity; 1. Pharmacokinetic Approaches for Cardiac Prevention; 2. Pharmacogenetic Approaches for Cardiac Prevention; 3. Chemo Protectants and Adjunctive Therapies to Reduce Cardiotoxicity; References; Chapter 8 Antitumor Antibiotics: Newer AnthracyclinesNew Anthracyclines; References; Chapter 9; Microtubule Inhibitors; Microtubule Inhibitors; Paclitaxel; Docetaxel; Vinca Alkaloids; Eribulin; Ixabepilone; References; Chapter 10; Hormonal Therapy; Estrogens; Aromatase Inhibitors; Progestins; Tamoxifen; Androgen Deprivation Therapy; Flutamide; Leuprolide; Cyproterone Acetate; References; Chapter 11; Immunotherapy; Interleukin; Interferon; References; Chapter 12; Monoclonal Antibodies; Trastuzumab; Rituximab; Alemtuzumab; Bevacizumab; Cetuximab; Gemtuzumab; Ibritumomab; Tositumomab; References Chapter 13Tyrosine Kinase Inhibitors; Imatinib; Dasatinib; Nilotinib; Sunitinib; Sorafenib; Lapatinib; Erlotinib and Geftinib; Other Tyrosine Kinase Inhibitors; References; Chapter 14; Topoisomerase-1 Inhibitors and Miscellaneous Drugs; Topoisomerase-1 Inhibitors; Irinotecan (CAMPTOSAR) and Topotecan (Hycamtin); Other Miscellaneous Drugs; Tretinoin; Arsenic Trioxide (Trisenox); References; About the Editors; Index; Blank Page Cardiology. http://id.loc.gov/authorities/subjects/sh85020214 Chemotherapy. http://id.loc.gov/authorities/subjects/sh85023041 Cardiology https://id.nlm.nih.gov/mesh/D002309 Drug Therapy https://id.nlm.nih.gov/mesh/D004358 Cardiologie. Chimiothérapie. HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Cardiology fast Chemotherapy fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85020214 http://id.loc.gov/authorities/subjects/sh85023041 https://id.nlm.nih.gov/mesh/D002309 https://id.nlm.nih.gov/mesh/D004358 |
| title | Cardiotoxicity of chemotherapeutic agents / |
| title_auth | Cardiotoxicity of chemotherapeutic agents / |
| title_exact_search | Cardiotoxicity of chemotherapeutic agents / |
| title_full | Cardiotoxicity of chemotherapeutic agents / Gregg M. Lanier, Jalaj Garg and Neeraj Shah, editors. |
| title_fullStr | Cardiotoxicity of chemotherapeutic agents / Gregg M. Lanier, Jalaj Garg and Neeraj Shah, editors. |
| title_full_unstemmed | Cardiotoxicity of chemotherapeutic agents / Gregg M. Lanier, Jalaj Garg and Neeraj Shah, editors. |
| title_short | Cardiotoxicity of chemotherapeutic agents / |
| title_sort | cardiotoxicity of chemotherapeutic agents |
| topic | Cardiology. http://id.loc.gov/authorities/subjects/sh85020214 Chemotherapy. http://id.loc.gov/authorities/subjects/sh85023041 Cardiology https://id.nlm.nih.gov/mesh/D002309 Drug Therapy https://id.nlm.nih.gov/mesh/D004358 Cardiologie. Chimiothérapie. HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Cardiology fast Chemotherapy fast |
| topic_facet | Cardiology. Chemotherapy. Cardiology Drug Therapy Cardiologie. Chimiothérapie. HEALTH & FITNESS Diseases General. MEDICAL Clinical Medicine. MEDICAL Diseases. MEDICAL Evidence-Based Medicine. MEDICAL Internal Medicine. Chemotherapy |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1540068 |
| work_keys_str_mv | AT laniergreggm cardiotoxicityofchemotherapeuticagents AT gargjalaj cardiotoxicityofchemotherapeuticagents AT shahneeraj cardiotoxicityofchemotherapeuticagents |